gene therapy stock focuses on RRP treatment By Investing.com
Precigen, Inc. (NASDAQ:), a biotechnology company specializing in gene and cell therapies with a market capitalization of $318 million, has recently undergone significant strategic shifts to focus on its lead candidate PRGN-2012 for the treatment of recurrent respiratory papillomatosis (RRP). This analysis examines Precigen’s current position, future prospects, and the potential impact of its strategic decisions on shareholder value. According to InvestingPro data, the stock has shown significant price volatility, with a beta of 1.65, indicating higher market sensitivity than average.
Want deeper insights? InvestingPro offers 13 additional investment tips and comprehensive analysis for PGEN, helping investors make more informed…
